Amgen
Search results
2 days ago · “As the most comprehensive and diverse HIV prevention trial program ever conducted, the PURPOSE program embodies both the scientific and person-centered innovations that Gilead believes are critical to help end the HIV epidemic for everyone, everywhere,” said Jared Baeten, MD, PhD, Senior Vice President, Clinical Development and HIV Franchise Head, Gilead Sciences.
2 days ago · Stock analysis for Gilead Sciences Inc (GILD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
2 days ago · Gilead Sciences is a sizable biopharmaceutical player with a portfolio of drugs that treat life-threatening diseases like HIV, viral hepatitis, and cancer. Over the trailing 12 months, GILD ...
4 days ago · Jul. 22, 2024, 12:00 PM. Gilead Sciences (NASDAQ:GILD) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below offers a ...
Jul 16, 2024 · PURPOSE 1 is the first HIV prevention trial to intentionally include pregnant and lactating women. In June, the topline results from an interim analysis of the Phase 3 trial were announced, demonstrating 100% efficacy for the investigational use of HIV prevention in cisgender women.
2 days ago · See the latest Gilead Sciences GILD stock price (NASDAQ: GILD), related news, valuation, dividends and more to help you make your investing decisions.
Jul 17, 2024 · Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
